Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Shukui Qin, Stephen L Chan et al. · The Lancet · 2023

Cited by 737 works. doi:10.1016/s0140-6736(23)00961-3

Authors

References